-
Randomized Double-blind Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Safety Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
In this research a study drug named XEN1101 is being tested for the treatment of seizures. XEN1101 is a study drug because its safety, effectiveness ... -
Roadster 3
The purpose of this research study is intended to evaluate real world usage of the ENROUTE® Transcarotid Stent when used with the ENROUTE® Transcarotid Neuroprotection ... -
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POETYK-SLE-2)
This study is a double-blinded 52-week clinical trial to evaluate the efficacy and safety of deucravacitinib in adult participants with active Systemic Lupus Erythematosus (SLE ... -
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA
This is a phase 3 clinical trial that compares the effectiveness of two different treatment options in patients who have undergone surgery to remove high-risk ...
-
A Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-related Outcomes in Patients with Well-compensated (Child-Pugh A) Non-alcoholic Steatohepatitis (NASH) Cirrhosis
A Randomized Double-blind Placebo-controlled study to determine the effect of randomized, once-daily, oral administration of 80 mg resmetirom versus matching placebo on patients with well-compensated ... -
A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiranin the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease with METAVIR Stage F2 to F4 Fibrosis
In this study, fazirsiran is being compared with a placebo for patients with alpha-1 antitrypsin deficiency-associated liver disease (AATD LD). A placebo is a liquid ... -
A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug called Sibeprenlimab. An investigational drug is a drug that ... -
A multicenter international randomized placebo controlled double-blind parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years or older.
OCEANIC-STROKE (study 20604) is a multicenter, international, randomized, placebo controlled, double-blind, parallel group, event driven phase 3 study. The purpose of this study is to ... -
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (POTEYK-SLE-1)
Researchers hope to learn more about whether deucravacitinib can help in the treatment of SLE and how safe it is to use in people with ... -
I-SPY 2 TRIAL -Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2
The I-SPY 2.2 study is a way to improve how we treat breast cancer. It uses a plan to test new treatments and find ...